LINCOLN, Neb., June 13, 2023 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced today that it has launched My CatScan™ 2.0, a significantly upgraded and improved version of the test from a leader in genetic screening for cats.
With the addition of 39 new diseases and genetic traits, My CatScan 2.0 is the latest genetic screening designed exclusively for cats, now offering information on more than 120 genetic health conditions. The test is designed to be a hassle-free experience for both feline companions and owners, utilizing a simple, noninvasive cheek swab method.
"At Neogen, we are committed to revolutionizing feline health through comprehensive genomic screening," said Dr. Robert Westra, Associate Medical Director at Neogen. "With the expanded analysis provided by My CatScan 2.0, we provide cat parents, feline breeders, and veterinarians with a greater depth of knowledge to provide insights about the health and well-being of their feline companions."
My CatScan 2.0 also delivers insights tailored to specific needs. Results can be categorized by breed, organ system, symptoms, or other factors, providing valuable information to make informed decisions about a cat's health.
Every cat, regardless of age or breed, can benefit from a deeper understanding of their genetic health. Genetic testing provides a number of advantages for cat owners, breeders, and veterinarians alike, including:
My CatScan 2.0 is now available for purchase via www.mycatscan.com. For more information, please contact Neogen's customer success team at This email address is being protected from spambots. You need JavaScript enabled to view it. or call 509.483.5950.
About Neogen
Neogen Corporation develops and markets comprehensive solutions dedicated to food and animal safety, operating with the intention to "Every day, protect the people and animals we care about." The Company's Food Safety segment markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases, and sanitation concerns. Neogen's Animal Safety segment is a leader in the development of genomic solutions along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care, and disinfectants, as well as rodent and insect control solutions.
Media Contact:
Maree Smith, Marketing Manager
763.244.6085 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$11.74 |
Daily Change: | -0.21 -1.76 |
Daily Volume: | 4,785,622 |
Market Cap: | US$2.550B |
January 21, 2025 January 10, 2025 December 17, 2024 October 10, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load